Bruce Zetter is a pioneer in understanding how cell movement affects tumor metastasis. In 1980, he made the key discovery that interferon alpha, which inhibits viral proliferation, also inhibits the locomotion of endothelial cells necessary for angiogenesis. His work led to the use of interferon alpha to treat hemangiomas.

Dr. Zetter's laboratory's current focus is on tumor metastasis and on identifying diagnostic and prognostic markers that can guide treatment decisions, including a new prognostic marker for prostate cancer. Specifically, the investigators are looking at:

  • The mechanisms used by cancer cells to spread or metastasize to distant sites.
  • The genetic, molecular and cellular changes that occur as tumors undergo progression from benign to aggressive.
  • The development of new markers for the diagnosis and prognosis of human cancers.
  • The development of novel therapeutic treatments for metastatic human cancers.

The Zetter lab has developed a panel of markers to predict which tumors are likely to metastasize or to have already produced metastatic colonies. The prototype for this type of molecule is thymosin Beta-15, which stimulates cell migration and promotes metastasis in prostate cancer cells. Tumors in which thymosin Beta-15 cannot be detected are unlikely to develop metastases and may not warrant aggressive treatment, while those expressing thymosin B -15 are more likely to have disseminated metastases and are candidates for aggressive systemic therapy.


Dr. Zetter received a PhD from the University of Rhode Island. He completed postdoctoral fellowships at MIT and at the Salk Institute in San Diego. He has received numerous national and international awards for his work in the field of cancer research, including a Faculty Research Award from the American Cancer Society and the MERIT award from the US National Cancer Institute.


Publications powered by Harvard Catalyst Profiles

  1. Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein. PLoS One. 2021; 16(4):e0250780. View abstract
  2. Unbiased Phenotype-Based Screen Identifies Therapeutic Agents Selective for Metastatic Prostate Cancer. Front Oncol. 2020; 10:594141. View abstract
  3. Prohibitin regulates mTOR pathway via interaction with FKBP8. Front Med. 2020 Dec 01. View abstract
  4. Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice. Biomaterials. 2021 Jan; 266:120431. View abstract
  5. Lipidation Approaches Potentiate Adjuvant-Pulsed Immune Surveillance: A Design Rationale for Cancer Nanovaccine. Front Bioeng Biotechnol. 2020; 8:787. View abstract
  6. Developing a novel FRET assay, targeting the binding between Antizyme-AZIN. Sci Rep. 2019 03 15; 9(1):4632. View abstract
  7. Author Correction: Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. Nat Biomed Eng. 2018 Dec; 2(12):968. View abstract
  8. Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. Nat Biomed Eng. 2018 11; 2(11):850-864. View abstract
  9. Synthesis and anticancer activity of novel water soluble benzimidazole carbamates. Eur J Med Chem. 2018 Jan 20; 144:372-385. View abstract
  10. Prohibitin 1 regulates tumor cell apoptosis via the interaction with X-linked inhibitor of apoptosis protein. J Mol Cell Biol. 2016 06; 8(3):282-5. View abstract
  11. Physical nanoscale conduit-mediated communication between tumour cells and the endothelium modulates endothelial phenotype. Nat Commun. 2015 Dec 16; 6:8671. View abstract
  12. Biomaterials for mRNA delivery. Biomater Sci. 2015 Dec; 3(12):1519-33. View abstract
  13. The Contribution of Angiogenesis to the Process of Metastasis. Cancer J. 2015 Jul-Aug; 21(4):267-73. View abstract
  14. Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment. Proc Natl Acad Sci U S A. 2015 Jun 23; 112(25):7779-84. View abstract
  15. Identification of genes regulating migration and invasion using a new model of metastatic prostate cancer. BMC Cancer. 2014 May 30; 14:387. View abstract
  16. Hybrid lipid-polymer nanoparticles for sustained siRNA delivery and gene silencing. Nanomedicine. 2014 Jul; 10(5):897-900. View abstract
  17. Advancing treatment of metastatic cancers: from research to communication--where do we need to go? Future Oncol. 2014; 10(9):1535-40. View abstract
  18. Regulation of epithelial plasticity by miR-424 and miR-200 in a new prostate cancer metastasis model. Sci Rep. 2013 Nov 06; 3:3151. View abstract
  19. Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res. 2013 Oct 15; 73(20):6359-74. View abstract
  20. Cytoskeletal stiffness, friction, and fluidity of cancer cell lines with different metastatic potential. Clin Exp Metastasis. 2013 Mar; 30(3):237-50. View abstract
  21. Surviving cancer. Nat Med. 2012; 18(6):851. View abstract
  22. Insulin-like growth factors promote vasculogenesis in embryonic stem cells. PLoS One. 2012; 7(2):e32191. View abstract
  23. Forty-year journey of angiogenesis translational research. Sci Transl Med. 2011 Dec 21; 3(114):114rv3. View abstract
  24. A role for collagen XXIII in cancer cell adhesion, anchorage-independence and metastasis. Oncogene. 2012 May 03; 31(18):2362-72. View abstract
  25. Knockdown of antizyme inhibitor decreases prostate tumor growth in vivo. Amino Acids. 2012 Feb; 42(2-3):549-58. View abstract
  26. Evidence of a role for antizyme and antizyme inhibitor as regulators of human cancer. Mol Cancer Res. 2011 Oct; 9(10):1285-93. View abstract
  27. miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene. 2011 Oct 27; 30(43):4386-98. View abstract
  28. Regenerative protein thymosin beta-4 is a novel regulator of purinergic signaling. FASEB J. 2011 Mar; 25(3):907-15. View abstract
  29. Quantitative proteomics analysis reveals molecular networks regulated by epidermal growth factor receptor level in head and neck cancer. J Proteome Res. 2010 Jun 04; 9(6):3073-82. View abstract
  30. Collagen XXIII: a potential biomarker for the detection of primary and recurrent non-small cell lung cancer. Cancer Epidemiol Biomarkers Prev. 2010 May; 19(5):1362-72. View abstract
  31. Self-assembled gold nanoparticle molecular probes for detecting proteolytic activity in vivo. ACS Nano. 2010 Mar 23; 4(3):1511-20. View abstract
  32. Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells. Proc Natl Acad Sci U S A. 2010 Feb 09; 107(6):2503-8. View abstract
  33. Differential regulation of human thymosin beta 15 isoforms by transforming growth factor beta 1. Genes Chromosomes Cancer. 2009 Jun; 48(6):502-9. View abstract
  34. Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression. Clin Cancer Res. 2009 Feb 01; 15(3):1024-31. View abstract
  35. The scientific contributions of M. Judah Folkman to cancer research. Nat Rev Cancer. 2008 08; 8(8):647-54. View abstract
  36. Meeting report: innovations in prostate cancer research. Cancer Res. 2008 Feb 01; 68(3):635-8. View abstract
  37. Antizyme, a mediator of ubiquitin-independent proteasomal degradation and its inhibitor localize to centrosomes and modulate centriole amplification. Oncogene. 2008 Jan 24; 27(5):604-13. View abstract
  38. Assessing enzyme activities using stable isotope labeling and mass spectrometry. Mol Cell Proteomics. 2007 Oct; 6(10):1771-7. View abstract
  39. Thymosin beta-NB is the human isoform of rat thymosin beta15. Ann N Y Acad Sci. 2007 Sep; 1112:286-96. View abstract
  40. Collagen XXIII expression is associated with prostate cancer recurrence and distant metastases. Clin Cancer Res. 2007 May 01; 13(9):2634-42. View abstract
  41. Regulation of cell proliferation by the antizyme inhibitor: evidence for an antizyme-independent mechanism. J Cell Sci. 2006 Jun 15; 119(Pt 12):2583-91. View abstract
  42. Enhanced analysis of metastatic prostate cancer using stable isotopes and high mass accuracy instrumentation. J Proteome Res. 2006 May; 5(5):1224-31. View abstract
  43. Proteomics in tumor progression and metastasis. Ann N Y Acad Sci. 2005 Nov; 1059:1-10. View abstract
  44. Ubiquitin-independent degradation and its implication in cancer. Future Oncol. 2005 Oct; 1(5):567-70. View abstract
  45. Use of thymosin beta15 as a urinary biomarker in human prostate cancer. Prostate. 2005 Jul 01; 64(2):116-27. View abstract
  46. Development of a sensitive and specific enzyme-linked immunosorbent assay for thymosin beta15, a urinary biomarker of human prostate cancer. Clin Biochem. 2005 Jun; 38(6):558-71. View abstract
  47. Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. J Cell Biol. 2005 Feb 14; 168(4):643-53. View abstract
  48. Cancer biomarkers: knowing the present and predicting the future. Future Oncol. 2005 Feb; 1(1):37-50. View abstract
  49. Oxidative stress and thioredoxin-interacting protein promote intravasation of melanoma cells. Exp Cell Res. 2004 Nov 01; 300(2):297-307. View abstract
  50. Antizyme targets cyclin D1 for degradation. A novel mechanism for cell growth repression. J Biol Chem. 2004 Oct 01; 279(40):41504-11. View abstract
  51. Identification of a transcriptional profile associated with in vitro invasion in non-small cell lung cancer cell lines. . 2004 Jul; 3(7):624-31. View abstract
  52. Quantitative cancer proteomics: stable isotope labeling with amino acids in cell culture (SILAC) as a tool for prostate cancer research. Mol Cell Proteomics. 2004 Jul; 3(7):729-35. View abstract
  53. Expedition Inspiration Fund for Breast Cancer Research Meeting 2003. Breast Cancer Res Treat. 2003 Jul; 80(2):139-44. View abstract
  54. Type XXIII collagen, a new transmembrane collagen identified in metastatic tumor cells. J Biol Chem. 2003 Jun 06; 278(23):20989-94. View abstract
  55. Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. Neoplasia. 2003 Jan-Feb; 5(1):32-40. View abstract
  56. Cancer. The silence of the genes. Nature. 2002 Oct 10; 419(6907):572-3. View abstract
  57. Gene therapy of prostate cancer with the soluble vascular endothelial growth factor receptor Flk1. . 2002 Sep-Oct; 1(5):548-53. View abstract
  58. Shifting paradigms in tumor metastasis: challenges and opportunities. . 2002 Sep-Oct; 1(5):582-5. View abstract
  59. Tumor vascularity: evaluation in a murine model with contrast-enhanced color Doppler US effect of angiogenesis inhibitors. Radiology. 2002 Feb; 222(2):460-7. View abstract
  60. DEF-1/ASAP1 is a GTPase-activating protein (GAP) for ARF1 that enhances cell motility through a GAP-dependent mechanism. J Biol Chem. 2002 Mar 08; 277(10):7962-9. View abstract
  61. Hold that line. Angiomotin regulates endothelial cell motility. J Cell Biol. 2001 Mar 19; 152(6):F35-6. View abstract
  62. Molecular cloning and structural characterization of the rat thymosin beta15 gene. Gene. 2000 Dec 30; 260(1-2):37-44. View abstract
  63. C-terminal variations in beta-thymosin family members specify functional differences in actin-binding properties. J Cell Biochem. 2000 Mar; 77(2):277-87. View abstract
  64. Motility and invasion are differentially modulated by Rho family GTPases. Oncogene. 2000 Jan 27; 19(4):580-91. View abstract
  65. Interaction of the Ras-related protein associated with diabetes rad and the putative tumor metastasis suppressor NM23 provides a novel mechanism of GTPase regulation. Proc Natl Acad Sci U S A. 1999 Dec 21; 96(26):14911-8. View abstract
  66. Sensitivity to polyamine-induced growth arrest correlates with antizyme induction in prostate carcinoma cells. Cancer Res. 1999 Dec 15; 59(24):6109-12. View abstract
  67. Corticotropin-releasing hormone stimulates angiogenesis and epithelial tumor growth in the skin. J Invest Dermatol. 1999 Nov; 113(5):838-42. View abstract
  68. Vascular endothelial growth factor-induced migration of vascular smooth muscle cells in vitro. Microvasc Res. 1999 Sep; 58(2):128-36. View abstract
  69. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci U S A. 1998 May 12; 95(10):5579-83. View abstract
  70. Thymosin beta15 expression in tumor cell lines with varying metastatic potential. Clin Exp Metastasis. 1998 Apr; 16(3):227-33. View abstract
  71. Angiogenesis and tumor metastasis. Annu Rev Med. 1998; 49:407-24. View abstract
  72. The role of cell motility in prostate cancer. Cancer Metastasis Rev. 1998-1999; 17(4):449-58. View abstract
  73. Platelet-derived growth factor and fibronectin-stimulated migration are differentially regulated by the Rac and extracellular signal-regulated kinase pathways. J Biol Chem. 1997 Dec 05; 272(49):30688-92. View abstract
  74. On target with tumor blood vessel markers. Nat Biotechnol. 1997 Nov; 15(12):1243-4. View abstract
  75. Localization and quantitation of expression of the cell motility-related protein thymosin beta15 in human breast tissue. Mod Pathol. 1997 Nov; 10(11):1106-12. View abstract
  76. Isolation of a mouse cDNA encoding mSTI1, a stress-inducible protein containing the TPR motif. Gene. 1997 Jul 31; 194(2):277-82. View abstract
  77. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest Ophthalmol Vis Sci. 1997 Apr; 38(5):817-23. View abstract
  78. Stress-inducible, murine protein mSTI1. Characterization of binding domains for heat shock proteins and in vitro phosphorylation by different kinases. J Biol Chem. 1997 Jan 17; 272(3):1876-84. View abstract
  79. Signaling mechanisms in growth factor-stimulated cell motility. Stem Cells. 1997; 15(4):259-67. View abstract
  80. Thymosin beta 15: a novel regulator of tumor cell motility upregulated in metastatic prostate cancer. Nat Med. 1996 Dec; 2(12):1322-8. View abstract
  81. Cell motility in breast cancer. Cancer Treat Res. 1996; 83:303-23. View abstract
  82. Differential endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor. Growth Factors. 1996; 13(1-2):57-64. View abstract
  83. A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth. Biochem Cell Biol. 1996; 74(6):853-62. View abstract
  84. Identification of an endogenous inhibitor of prostatic carcinoma cell growth. Nat Med. 1995 Oct; 1(10):1040-5. View abstract
  85. The chemotactic response to PDGF-BB: evidence of a role for Ras. J Cell Biol. 1995 Aug; 130(3):725-31. View abstract
  86. Isolation of a mouse cDNA encoding MTJ1, a new murine member of the DnaJ family of proteins. Gene. 1995 Feb 14; 153(2):249-54. View abstract
  87. Increased stem cell factor release by hemangioma-derived endothelial cells. Lab Invest. 1995 Feb; 72(2):166-73. View abstract
  88. Excess early signaling activity inhibits cellular chemotaxis toward PDGF-BB. Oncogene. 1994 May; 9(5):1429-35. View abstract
  89. Regulation of chemotaxis by the platelet-derived growth factor receptor-beta. Nature. 1994 Feb 03; 367(6462):474-6. View abstract
  90. Functional domains of the insulin receptor responsible for chemotactic signaling. J Biol Chem. 1994 Jan 07; 269(1):100-4. View abstract
  91. Mast cell accumulation at sites of murine tumor implantation: implications for angiogenesis and tumor metastasis. Invasion Metastasis. 1994-1995; 14(1-6):395-408. View abstract
  92. Adhesion molecules in tumor metastasis. Semin Cancer Biol. 1993 Aug; 4(4):219-29. View abstract
  93. Laminin regulates a tumor cell chemotaxis receptor through the laminin-binding integrin subunit alpha 6. Cancer Res. 1993 Jun 01; 53(11):2661-6. View abstract
  94. Inhibition of cell motility after nm23 transfection of human and murine tumor cells. Cancer Res. 1993 May 01; 53(9):1971-3. View abstract
  95. Selective stimulation of prostatic carcinoma cell proliferation by transferrin. Proc Natl Acad Sci U S A. 1992 Jul 01; 89(13):6197-201. View abstract
  96. Mast cells and angiogenesis. Semin Cancer Biol. 1992 Apr; 3(2):73-9. View abstract
  97. The c-kit receptor ligand functions as a mast cell chemoattractant. Blood. 1992 Feb 15; 79(4):958-63. View abstract
  98. Adhesive interactions in angiogenesis and metastasis. Pharmacol Ther. 1992; 53(2):239-60. View abstract
  99. The cellular basis for prostate cancer metastasis. Adv Exp Med Biol. 1992; 324:39-43. View abstract
  100. In vitro and in vivo consequences of VLA-2 expression on rhabdomyosarcoma cells. Science. 1991 Mar 29; 251(5001):1600-2. View abstract
  101. Multiple ligand binding functions for VLA-2 (alpha 2 beta 1) and VLA-3 (alpha 3 beta 1) in the integrin family. Cell Differ Dev. 1990 Dec 02; 32(3):229-38. View abstract
  102. Cell motility and the extracellular matrix. Curr Opin Cell Biol. 1990 Oct; 2(5):850-6. View abstract
  103. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta. 1990 Jun 01; 1032(1):89-118. View abstract
  104. The cellular basis of site-specific tumor metastasis. N Engl J Med. 1990 Mar 01; 322(9):605-12. View abstract
  105. Cell motility in angiogenesis and tumor metastasis. Cancer Invest. 1990; 8(6):669-71. View abstract
  106. Tumor cell interactions with elastin: implications for pulmonary metastasis. Am Rev Respir Dis. 1989 Nov; 140(5):1458-62. View abstract
  107. Stimulation of mast cell chemotaxis by interleukin 3. J Exp Med. 1989 Oct 01; 170(4):1421-6. View abstract
  108. Stimulation of human prostatic carcinoma cell growth by factors present in human bone marrow. J Clin Invest. 1989 Jul; 84(1):43-50. View abstract
  109. Membrane-bound protein kinase C modulates receptor affinity and chemotactic responsiveness of Lewis lung carcinoma sublines to an elastin-derived peptide. J Biol Chem. 1989 Jun 25; 264(18):10614-20. View abstract
  110. Identification of a tumor cell receptor for VGVAPG, an elastin-derived chemotactic peptide. J Cell Biol. 1988 Nov; 107(5):1987-93. View abstract
  111. Angiogenic activity of adipose tissue. Biochem Biophys Res Commun. 1988 May 31; 153(1):347-52. View abstract
  112. Angiogenesis. State of the art. Chest. 1988 Mar; 93(3 Suppl):159S-166S. View abstract
  113. Lewis lung carcinoma variants with differing metastatic specificities adhere preferentially to different defined extracellular matrix molecules. Invasion Metastasis. 1988; 8(2):103-17. View abstract
  114. Human iliac artery endothelial cells express both genes encoding the chains of platelet-derived growth factor (PDGF) and synthesize PDGF-like mitogen. J Cell Physiol. 1987 Aug; 132(2):376-80. View abstract
  115. Monocyte adhesion to subendothelial components. Blood. 1987 Apr; 69(4):1265-8. View abstract
  116. Assay of capillary endothelial cell migration. Methods Enzymol. 1987; 147:135-44. View abstract
  117. Melanoma cell adhesion to defined extracellular matrix components. Biochem Biophys Res Commun. 1986 Sep 14; 139(2):515-22. View abstract
  118. In situ labelling of vascular endothelium with fluorescent acetylated low density lipoprotein. Histochem J. 1985 Dec; 17(12):1309-20. View abstract
  119. Metastatic potential of B16 melanoma cells after in vitro selection for organ-specific adherence. J Cell Biol. 1985 Sep; 101(3):720-4. View abstract
  120. An in vivo assay for chemoattractant activity. Lab Invest. 1985 Sep; 53(3):362-8. View abstract
  121. Identification and isolation of endothelial cells based on their increased uptake of acetylated-low density lipoprotein. J Cell Biol. 1984 Dec; 99(6):2034-40. View abstract
  122. The nonluteal porcine ovary as a source of angiogenic activity. Endocrinology. 1984 Nov; 115(5):1672-7. View abstract
  123. Organ-specific adhesion of metastatic tumor cells in vitro. Science. 1984 Jun 08; 224(4653):1113-5. View abstract
  124. Stimulation of rat peritoneal mast cell migration by tumor-derived peptides. Cancer Res. 1983 Dec; 43(12 Pt 1):5857-61. View abstract
  125. Capillary endothelial cell migration: stimulating activity of aqueous humor from patients with ocular cancers. J Natl Cancer Inst. 1983 Sep; 71(3):501-5. View abstract
  126. Stimulation of increased capillary endothelial cell motility by chondrosarcoma cell-derived factors. Cancer Res. 1983 Jul; 43(7):3281-6. View abstract
  127. Retinal vascular endothelial cells and pericytes. Differential growth characteristics in vitro. Invest Ophthalmol Vis Sci. 1983 Apr; 24(4):470-80. View abstract
  128. Cultured endothelial cells derived from the human iliac arteries. In Vitro. 1982 Oct; 18(10):859-66. View abstract
  129. In vitro characteristics of endothelium from hemangiomas and vascular malformations. Surgery. 1982 Aug; 92(2):348-53. View abstract
  130. Migration of cultured vascular cells in response to plasma and platelet-derived factors. J Cell Sci. 1982 Aug; 56:71-82. View abstract
  131. Absence of mast cells in diabetic retinopathy. Microvasc Res. 1982 Jul; 24(1):87-93. View abstract
  132. Urine from patients with transitional-cell carcinoma stimulates migration of capillary endothelial cells. N Engl J Med. 1981 Oct 08; 305(15):869-74. View abstract
  133. The stimulation of capillary endothelial cell migration by aqueous humor. J Surg Res. 1981 Mar; 30(3):262-8. View abstract
  134. The endothelial cells of large and small blood vessels. Diabetes. 1981; 30(Suppl 2):24-8. View abstract
  135. Platelet-dependent stimulation of prostacyclin synthesis by platelet-derived growth factor. Nature. 1980 Dec 11; 288(5791):600-2. View abstract
  136. Mast cell heparin stimulates migration of capillary endothelial cells in vitro. J Exp Med. 1980 Oct 01; 152(4):931-44. View abstract
  137. Inhibition of cell motility by interferon. Science. 1980 May 02; 208(4443):516-8. View abstract
  138. Migration of capillary endothelial cells is stimulated by tumour-derived factors. Nature. 1980 May 01; 285(5759):41-3. View abstract
  139. Long-term culture of capillary endothelial cells. Proc Natl Acad Sci U S A. 1979 Oct; 76(10):5217-21. View abstract
  140. LETS protein in normal and pathological human oral epithelium. J Dent Res. 1979 Jan; 58(1):484-8. View abstract
  141. Stimulation of human vascular endothelial cell growth by a platelet-derived growth factor and thrombin. J Supramol Struct. 1979; 11(3):361-70. View abstract
  142. The isolation of vascular endothelial cell lines with altered cell surface and platelet-binding properties. Cell. 1978 Jul; 14(3):501-9. View abstract
  143. Are high-molecular-weight glycoproteins regulators of cellular growth? Ann N Y Acad Sci. 1978 Jun 20; 312:293-8. View abstract
  144. Role of the high-molecular-weight glycoprotein in cellular morphology, adhesion, and differentiation. Ann N Y Acad Sci. 1978 Jun 20; 312:299-316. View abstract
  145. Control of proliferation of human vascular endothelial cells. Characterization of the response of human umbilical vein endothelial cells to fibroblast growth factor, epidermal growth factor, and thrombin. J Cell Biol. 1978 Jun; 77(3):774-88. View abstract
  146. Expression of a high molecular weight cell surface glycoprotein (LETS protein) by preimplantation mouse embryos and teratocarcinoma stem cells. Proc Natl Acad Sci U S A. 1978 May; 75(5):2324-8. View abstract
  147. Mitogenic response of cells in tissue culture to thrombin. Natl Cancer Inst Monogr. 1978 May; (48):157-65. View abstract
  148. Factors involved in the modulation of cell proliferation in vivo and in vitro: the role of fibroblast and epidermal growth factors in the proliferative response of mammalian cells. In Vitro. 1978 Jan; 14(1):85-118. View abstract
  149. Thrombin potentiates the mitogenic response of cultured fibroblasts to serum and other growth promoting agents. J Cell Physiol. 1977 Aug; 92(2):233-9. View abstract
  150. Binding and internalization of thrombin by normal and transformed chick cells. Proc Natl Acad Sci U S A. 1977 Feb; 74(2):596-600. View abstract
  151. The use of fibroblast and epidermal growth factors to lower the serum requirement for growth of normal diploid cells in early passage: a new method for cloning. Dev Biol Stand. 1976 Dec 13-15; 37:109-30. View abstract
  152. Effects of protease treatment on growth, morphology, adhesion, and cell surface proteins of secondary chick embryo fibroblasts. Cell. 1976 Mar; 7(3):407-12. View abstract
  153. Post-transcriptional regulation of T4 enzyme synthesis. Arch Biochem Biophys. 1974 Jun; 162(2):560-7. View abstract
  154. Evidence that more deoxynucleotide kinase mRNA is transcribed than translated during T4 infection of Escherichia coli. Virology. 1972 Sep; 49(3):808-10. View abstract